Advanced/ Metastatic Hepatocellular Carcinoma Clinical Trial
Official title:
Phase 1b Open Label Dose Assessment Study of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC) With an Expansion Cohort in HCC Patients Expressing HER3 Who Have Progressed on First Line Sorafenib or Lenvatinib
This is a single-arm, allocation open label study. Phase 1 is a dose-finding phase in
patients with advanced/ metastatic hepatocellular carcinoma (HCC) who have progressed on
first line Sorafenib or Lenvatinib.
The primary objective of this study will be to establish the maximal tolerable dose (MTD) of
ASLAN001 (Varlitinib) in the study population
The secondary objectives include:
1. To evaluate the efficacy of ASLAN001 (Varlitinib), as measured by duration of response
(DoR), progression free survival (PFS), overall survival (OS) and disease control rate
(DCR)
2. To assess the ORR, DoR, PFS, DCR and OS by tumor EGFR/HER2/HER3/HER4 status
3. To identify tumor and host biomarkers predictive of treatment response or toxicity to
ASLAN001.
| Status | Recruiting |
| Enrollment | 22 |
| Est. completion date | May 5, 2021 |
| Est. primary completion date | May 5, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 21 Years to 99 Years |
| Eligibility |
Inclusion Criteria: 1. Patient must have unresectable or metastatic HCC with Childs Pugh status A with histologic confirmation. i) Subjects with only a radiologic diagnosis of HCC may be enrolled for screening in the study but histological confirmation is mandatory prior to the start of study therapy. ii) Evaluable tumor tissue (formalin-fixed, paraffin embedded archival or recent acquisition) must have 15 unstained slides for correlative studies. If archived samples are not available, subjects must consent to a pre-treatment fresh biopsy as a condition of protocol participation. 2. Patients must have failed Sorafenib or Lenvatinib due to disease progression or intolerance. 3. Presence of radiographically measurable disease based on RECIST v1.1. 4. No evidence of biliary duct obstruction, unless obstruction is controlled by local treatment or, in whom the biliary tree can be decompressed by endoscopic or percutaneous stenting with subsequent reduction in bilirubin to below 1.5 x upper level of normal (ULN). 5. Patients age = 21 years at the time of written informed consent. 6. Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 7. Patient must be able to understand and willing to sign the informed consent form and donate tumor tissue (archival or fresh) for evaluation of relevant exploratory endpoints. 8. Patient with adequate organ and hematological function: a. Hematological function, as follows: i. Absolute neutrophil count (ANC) = 1.5 x 109/L ii. Platelet count = 80 x 10^9/L b. Renal functions, as follows: i. Serum creatinine = 1.5x ULN or eGFR > 60 mL/min/1.73m2 c. Hepatic function in addition to Childs Pugh score A: i. Total bilirubin = 1.5 x ULN ii. AST and ALT = 2.5 x ULN Expansion cohort 1. Patients must agree to a post treatment biopsy 2. HER3 expression on IHC 3. Other inclusion criteria as above Exclusion Criteria: 1. Patient with radiation or local treatment within the past 6 weeks for the target lesion(s). 2. Patients with major surgical procedures within 21 days prior to study entry. 3. Patient with brain lesion, known brain metastases (unless previously treated and well controlled for a period of at least 3 months). 4. Patient with malabsorption syndrome, diseases significantly affecting gastrointestinal function, resection of the stomach or small bowel, or difficulty in swallowing and retaining oral medications. 5. Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, diabetes, hypertension, or psychiatric illness/social situations that would limit compliance with study requirements. 6. Patients with any history of other malignancy unless in remission for more than 1 year. (Non-melanoma skin carcinoma and carcinoma-in-site of uterine cervix treated with curative intent is not exclusionary). 7. Female patients who are pregnant or breast feeding. 8. Patients who were previously treated with ASLAN001 (Varlitinib). 9. Patients who have received any investigational drug (or have used an investigational device) within the last 14 days before receiving the first dose of study medication. 10. Patient with unresolved or unstable serious toxicity ( = CTCAE 4.03 Grade 2) from prior administration of another investigational drug and/or prior cancer treatment. 11. Patients with a known history of HIV, decompensated cirrhosis, chronic active hepatitis or chronic persistent hepatitis. 12. Patients who need continuous treatment with proton pump inhibitors during the study period. 13. Any history or presence of clinically significant cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease or any other condition which in the opinion of the Investigator could jeopardize the safety of the patient or the validity of the study results |
| Country | Name | City | State |
|---|---|---|---|
| Singapore | National University Hospital | Singapore |
| Lead Sponsor | Collaborator |
|---|---|
| National University Hospital, Singapore |
Singapore,
Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan;4(1):156-65. — View Citation
Yang X, Wang W, Wang C, Wang L, Yang M, Qi M, Su H, Sun X, Liu Z, Zhang J, Qin X, Han B. Characterization of EGFR family gene aberrations in cholangiocarcinoma. Oncol Rep. 2014 Aug;32(2):700-8. doi: 10.3892/or.2014.3261. Epub 2014 Jun 13. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Definition of MTD (maximum tolerable dose) | The maximum tolerable dose is defined as the highest evaluated dose where < 1/6 patients experiences DLT during the DLT evaluation window. | up to 1 year since the start of treatment | |
| Secondary | Objective Response Rate | Defined as the proportion of patients with a response of Partial Response or Complete Response, as defined by RECIST v1.1 criteria. Measurable disease: Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of 10mm on CT scan Malignant lymph node: =15mm in short axis on CT scan Non-measurable disease: All other lesions, including small lesions (longest diameter <10mm or pathological lymph nodes with >10 to <15mm short axis) as well as truly non-measurable lesions |
up to 1 year since the start of treatment | |
| Secondary | Progression Free Survival | Defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined in accordance with RECIST v1.1 criteria. | up to 1 year since the start of treatment |